Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0369820150450020143
Jorunal of Korean Pharmaceutical Sciences
2015 Volume.45 No. 2 p.143 ~ p.149
Enhanced survival of human mesenchymal stem cells following co-delivery with glucagon-like peptide-1 analogue in fibrin gel
Jin Hye-Rim

Lee Woo-Jung
Lee Soong-Dong
Yi Tac-Ghee
Song Sun-Uk
Shim Ga-Yong
Oh Yu-Kyoung
Abstract
Here, we report that glucagon-like peptide-1 analogue liraglutide could enhance survival of human bone marrow-derived mesenchymal stem cells (hMSCs) following co-delivery in fibrin gel matrix. The hMSCs were treated with various concentrations (¡Â100 nM) of liraglutide. After 48 h, 100 nM liraglutide-treated hMSCs showed 1.4-fold higher cell viability than untreated hMSCs. Calcein staining for live cells and trypan blue staining for dead cells provided visual evidences that treatment of hMSCs with liraglutide increased cell survival. To evaluate the cell survival of hMSCs after in vivo transplantation, genomic DNA of hMSCs was quantified by quantitative real-time polymerase chain reaction by detecting human Alu element. Four days after transplantation, the survival of hMSCs co-transplanted with liraglutide (1.9 ¥ìg/kg) was 7.7-fold higher than that of plain hMSCs formulation. Taken together, our findings suggest the potential of liraglutide as a transplantation adjuvant for increasing in vivo survival of hMSCs.
KEYWORD
Mesenchymal stem cells, Liraglutide, Glucagon-like peptide-1, Cell survival, Co-delivery
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)